Jeiwook Chae BS, MS, PhD

Jeiwook Chae, since earning his PhD from the University of Virginia, Dr. Jeiwook (Jei) Chae has conducted research both in academic and industry settings, gaining invaluable experience in many aspects of discovery research, animal models for human diseases, and preclinical therapeutic testing. He has extensive experience and expertise in animal disease models, especially mouse tumour and fibrosis models as well as cell culture-based assays for the target discovery/validation and drug efficacy evaluation.

His postdoctoral research at Harvard University was primarily focused on elucidating the mechanism underlying spreading RNAi signals between cells, especially related to cancer biology. His collaborative preclinical research with a leading RNAi therapeutics company, Alnylam, provided important insights for the clinical development of RNAi therapeutics. Subsequently, he joined Bioneer, where he served as Director of Research and conducted preclinical evaluations of a siRNA-based drug technology as well as research into RNAi pipelines involving multiple diseases.

As Chief Business Development Officer at LegoChem Biosciences Dr. Chae currently leads company’s scientific endeavours and has guided academic and industry collaborations, advancing the clinical development of pipeline programs including antibiotics, anticoagulants, and Antibody-Drug Conjugates (ADC)- based cancer drug. The primary mission of Dr. Jei Chae and his colleagues in LegoChem Biosciences is to develop a clinically applicable ADC drug using a novel site-specific ADC technology developed by the company.